专利药品可及性的现实困境和制度优化——兼评药品专利池组织的运营  

The realistic dilemma and institutional optimization of the accessibility of patented medicines——a concurrent review on the operation of Medicines Patent Pool

作　　者：皇甫洁琼 钟彦[2] HUANGFU Jie-qiong;ZHONG Yan(Patent Examination Cooperation Center of the Patent Office,China National Intellectual Property Administration,Guangzhou 510535,China;China National Intellectual Property Administration,Beijing 100088,China)

机构地区：[1]国家知识产权局专利局专利审查协作广东中心,广州510535 [2]国家知识产权局,北京100088

出　　处：《中国新药杂志》2024年第9期864-867,共4页Chinese Journal of New Drugs

基　　金：国家知识产权局中高端人才发展研究平台2022年度课题项目:新冠疫情背景下药品专利池组织(MPP)的全球运营及对我国的影响(GP2215)。

摘　　要：为了解决中低收入国家的药物可及性问题,国际药品采购机构创建了药品专利池组织(Medicines Patent Pool, MPP),但一直未将中国纳入许可销售的范围内。本文对MPP的运营机制、MPP对我国的影响开展了研究,探讨我国可与MPP合作的前景和具体方式,将有助于为国内制药企业提供更多国际竞争和国际合作的可能,扩展我国药物在中低收入国家的市场占有率和使用率,为我国开拓提高国际影响力的途径提供借鉴。To address the issue of drug accessibility in low-and middle-income countries,the Medicines Patent Pool(MPP)was built by the International Medicines Purchasing Agency.However,China has not been included in the scope of licensed sales.This paper conducts a study on the operation mechanism of MPP and the its impact on China,and explores the prospects and specific ways in which China can cooperate with MPP,which will help provide domestic pharmaceutical companies with more possibilities for international competition and international cooperation,expand the market share and utilization rate of China's drugs in low-and middle-income countries,and provide a reference for China to develop ways to improve its international influence.

关 键 词：药品专利池 药物 专利 可及性 

分 类 号：R95[医药卫生—药学]